Home›Stock Screener›Biocon›Quarterly Results

Biocon Quarterly Results for Trading Insights

Latest Quarter Net Profit
₹199 Cr
QMar 2026
Quarterly Results

In Mar 2026, Biocon (BIOCON) reported revenue ₹4,537 Cr and net profit ₹199 Cr — revenue +2.8% YoY. Also explore BIOCON share price history to track price trends across different timeframes.

BIOCON Quarterly Results — Revenue, Profit & EPS Highlights

Biocon latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit BIOCON share price.

  • Revenue of ₹4,537 Cr in Mar 2026 (+4.2% vs Sept 2025, +2.8% vs Mar 2025)
  • Net Profit of ₹199 Cr in Mar 2026 (+49.6% vs Sept 2025, -56.6% vs Mar 2025)
  • EBITDA of ₹960 Cr in Mar 2026 (+8.6% vs Sept 2025)
  • Operating Margin of 20.0% in Mar 2026 (+1.0pp vs Sept 2025)
  • Earnings Per Share of ₹0.79 in Mar 2026 (+19.7% vs Sept 2025)

Biocon Quarterly Results — Revenue, EBITDA, Net Profit & EPS

BIOCON quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Mar 2026 Sept 2025 Mar 2025 Jun 2025 Dec 2025 QoQ YoY
Revenue (₹ Cr) 4,537 4,356 4,415 3,990 4,240 4.2% 2.8%
Net Profit (₹ Cr) 199 133 459 89 -52 - -
EBITDA (₹ Cr) 960 884 1,077 797 607 - -
EPS (₹) 0.79 0.66 2.88 0.26 1.08 - -
Operating Margin (%) 20.0% 19.0% 23.0% 18.0% 12.0% - -

BIOCON Share Price Trend — 1-Year Movement Across Quarterly Results

Biocon 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Compare with BIOCON DCF valuation to assess whether the stock is under or overvalued.

Profitability Ratios

Profit Margin 4.4%
EBITDA Margin 21.2%
Operating Margin 20.0%
ROE (Annual) 2.3%

Balance Sheet Highlights

Total Assets ₹63,651 Cr
Total Equity ₹34,032 Cr
Current Assets ₹17,180 Cr
Current Liabilities ₹12,960 Cr

Cash Flow Analysis

Operating Cash Flow ₹4,061 Cr
Investing Cash Flow ₹-203 Cr
Financing Cash Flow ₹-1,854 Cr
Net Cash Flow ₹2,004 Cr

Current Market Data

Current Price ₹421.10
Exchange NSE
Last Updated Jun 22, 2026

Revenue Trend (₹ Cr)

Jun 2025 3,990
Mar 2025 4,415
Sept 2025 4,356
Mar 2026 4,537

Net Profit Trend (₹ Cr)

Jun 2025 89
Mar 2025 459
Sept 2025 133
Mar 2026 199

Operating Margin Trend (%)

Jun 2025 18.0%
Mar 2025 23.0%
Sept 2025 19.0%
Mar 2026 20.0%

BIOCON vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Biocon latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Mar 2026 		₹441,069.70 Cr 1862.9 15,018 2,710 +1.0% +11.8% 18.0% 164.9
Divis Laboratories
Mar 2026 		₹180,186.80 Cr 6787.5 2,986 751 +4.4% +11.8% 25.2% 239.8
Torrent Pharmaceuti…
Mar 2026 		₹149,924.56 Cr 4457.0 4,111 364 +27.7% +42.2% 8.9% 387.2
Zydus Life Science
Mar 2026 		₹109,226.70 Cr 1085.5 7,569 1,341 +23.1% +18.8% 17.7% 85.8
Cipla
Mar 2026 		₹109,195.79 Cr 1415.7 6,612 543 -14.3% -4.0% 8.2% 206.1
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores